The antiangiogenic insulin receptor substrate-1 antisense oligonucleotide aganirsen impairs AU-rich mRNA stability by reducing 14-3-3β- tristetraprolin protein complex, reducing inflammation and psoriatic lesion size in patients

Journal of Pharmacology and Experimental Therapeutics

Volumn 349, Issue 4, 2014, Pages 107-117

  Colin, Sylvie ^a   Darné, Bernadette ^b   Kadi, Amin ^b   Ferry, Antoine ^a   Favier, Maryline ^c   Lesaffre, Corinne ^c   Conduzorgues, Jean Pascal ^d   Al Mahmood, Salman ^a   Doss, Nejib ^e  

^a Gene Signal Laboratories   (France)

^b Monitoring Force Group   (France)

^c INSTITUT COCHIN   (France)

^d AMATSI ^*  (France)

^e MILITARY HOSPITAL OF TUNIS   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; AU RICH ELEMENTS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; MALE; MICROVESSELS; MIDDLE AGED; OLIGONUCLEOTIDES; PILOT PROJECTS; PSORIASIS; RNA STABILITY; RNA, MESSENGER; SKIN; TREATMENT OUTCOME; TRISTETRAPROLIN;

EID: 84896457296     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.209346     Document Type: Article

References (37)

1. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, and Lawley TJ (1992) HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 99:683-690.
2. Al-Mahmood S, Colin S, Farhat N, Thorin E, Steverlynck C, and Chemtob S (2009) Potent in vivo antiangiogenic effects of GS-101 (5′- TATCCGGAGGGCTCGCCATGCTGCT-3′), an antisense oligonucleotide preventing the expression of insulin receptor substrate-1. J Pharmacol Exp Ther 329:496-504.
3. Anderson TW and Darling DA (1954) A test of goodness-of-fit. J Am Stat Assoc 49: 765-769.
4. Andrieu-Soler C, Berdugo M, Doat M, Courtois Y, BenEzra D, and Behar-Cohen F (2005) Downregulation of IRS-1 expression causes inhibition of corneal angiogenesis. Invest Ophthalmol Vis Sci 46:4072-4078.
5. Bak RO and Mikkelsen JG (2010) Regulation of cytokines by small RNAs during skin inflammation. J Biomed Sci 17:53.
6. Blackshear PJ, Lai WS, Kennington EA, Brewer G, Wilson GM, Guan X, and Zhou P (2003) Characteristics of the interaction of a synthetic human tristetraprolin tandem zinc finger peptide with AU-rich element-containing RNA substrates. J Biol Chem 278:19947-19955.
7. Cao H, Dzineku F, and Blackshear PJ (2003) Expression and purification of recombinant tristetraprolin that can bind to tumor necrosis factor-α mRNA and serve as a substrate for mitogen-activated protein kinases. Arch Biochem Biophys 412:106-120.
8. Caldarola G, De Simone C, Carbone A, Tulli A, Amerio P, and Feliciani C (2009) TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept. Int J Immunopathol Pharmacol 22:961-966.
9. Carballo E, Lai WS, and Blackshear PJ (1998) Feedback inhibition of macrophage tumor necrosis factor-α production by tristetraprolin. Science 281: 1001-1005.
10. Cloutier F, Lawrence M, Goody R, Lamoureux S, Al-Mahmood S, Colin S, Ferry A, Conduzorgues JP, Hadri A, and Cursiefen C, et al. (2012) Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administration. Invest Ophthalmol Vis Sci 53:1195-1203.
11. Coimbra S, Figueiredo A, Castro E, Rocha-Pereira P, and Santos-Silva A (2012) The roles of cells and cytokines in the pathogenesis of psoriasis. Int J Dermatol 51: 389-395, quiz 395-398.
12. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B, and Dvorak HF (1994) Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180: 1141-1146.
13. Detmar M, Brown LF, Schön MP, Elicker BM, Velasco P, Richard L, Fukumura D, Monsky W, Claffey KP, and Jain RK (1998) Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 111:1-6.
14. Feldman SR and Krueger GG (2005) Psoriasis assessment tools in clinical trials. Ann Rheum Dis 64 (Suppl 2):ii65-ii68; discussion ii69-ii73.
15. Ferrara N, Gerber HP, and LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676.
16. Heidenreich R, Röcken M, and Ghoreschi K (2009) Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol 90:232-248.
17. Henno A, Blacher S, Lambert CA, Deroanne C, Noël A, Lapière C, de la Brassinne M, Nusgens BV, and Colige A (2010) Histological and transcriptional study of angiogenesis and lymphangiogenesis in uninvolved skin, acute pinpoint lesions and established psoriasis plaques: an approach of vascular development chronology in psoriasis. J Dermatol Sci 57:162-169.
18. Ji RC (2012) Macrophages are important mediators of either tumor- or inflammation-induced lymphangiogenesis. Cell Mol Life Sci 69:897-914.
19. Johnson BA, Stehn JR, Yaffe MB, and Blackwell TK (2002) Cytoplasmic localization of tristetraprolin involves 14-3-3-dependent and -independent mechanisms. J Biol Chem 277:18029-18036.
20. Khabar KS (2010) Post-transcriptional control during chronic inflammation and cancer: a focus on AU-rich elements. Cell Mol Life Sci 67:2937-2955.
21. Koch S, Tugues S, Li X, Gualandi L, and Claesson-Welsh L (2011) Signal transduction by vascular endothelial growth factor receptors. Biochem J 437:169-183.
22. Kosaki A, Yamada K, Suga J, Otaka A, and Kuzuya H (1998) 14-3-3beta protein associates with insulin receptor substrate 1 and decreases insulin-stimulated phosphatidylinositol 39-kinase activity in 3T3L1 adipocytes. J Biol Chem 273: 940-944.
23. Krueger JG, Wolfe JT, Nabeya RT, Vallat VP, Gilleaudeau P, Heftler NS, Austin LM, and Gottlieb AB (1995) Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 182:2057-2068.
24. Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS, and Blackshear PJ (1999) Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor a mRNA. Mol Cell Biol 19:4311-4323.
25. Nestle FO, Kaplan DH, and Barker J (2009) Psoriasis. N Engl J Med 361:496-509.
26. Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suárez-Fariñas M, Cardinale I, Khatcherian A, Gonzalez J, Pierson KC, and White TR, et al. (2008) Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 159:1092-1102.
27. Ogihara T, Isobe T, Ichimura T, Taoka M, Funaki M, Sakoda H, Onishi Y, Inukai K, Anai M, and Fukushima Y, et al. (1997) 14-3-3 protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain. J Biol Chem 272:25267-25274.
28. Oriente F, Andreozzi F, Romano C, Perruolo G, Perfetti A, Fiory F, Miele C, Beguinot F, and Formisano P (2005) Protein kinase C-alpha regulates insulin action and degradation by interacting with insulin receptor substrate-1 and 14-3-3 epsilon. J Biol Chem 280:40642-40649.
29. Orlinick JR and Chao MV (1998) TNF-related ligands and their receptors. Cell Signal 10:543-551.
30. Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, and Day RM (2012a) Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 380:738-746.
31. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, and Thompson EH, et al. (2012b) Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 366:1181-1189.
32. Sabat R, Sterry W, Philipp S, and Wolk K (2007) Three decades of psoriasis research: where has it led us? Clin Dermatol 25:504-509.
33. Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T, and Shibuya M (2001) Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 97: 785-791.
34. Schittek B (2011) The antimicrobial skin barrier in patients with atopic dermatitis. Curr Probl Dermatol 41:54-67.
35. Weger W (2010) Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 160:810-820.
36. Xiang X, Yuan M, Song Y, Ruderman N, Wen R, and Luo Z (2002) 14-3-3 facilitates insulin-stimulated intracellular trafficking of insulin receptor substrate 1. Mol Endocrinol 16:552-562.
37. Zhao J, Meyerkord CL, Du Y, Khuri FR, and Fu H (2011) 14-3-3 proteins as potential therapeutic targets. Semin Cell Dev Biol 22:705-712.